)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Atea Pharmaceuticals
Atea Pharmaceuticals (AVIR) investor relations material
Atea Pharmaceuticals Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary9 Nov, 2026
Executive summary
C-BEYOND met its primary and secondary endpoints, demonstrating non-inferiority of BEM/RZR versus SOF/VEL; C-FORWARD topline results are expected in early 2027.
AT-587 advanced into Phase 1 for chronic HEV; a Hercules Capital facility provides up to $200 million in financing.
Financial highlights
Q3 2026 operating expenses were $34.013 million, including $27.091 million of R&D and $6.922 million of G&A; operating loss was $34.013 million.
Q3 net loss was $32.162 million versus $42.0 million in Q3 2025; basic and diluted loss per share was $0.40 versus $0.53.
9M 2026 operating expenses were $117.120 million versus $126.0 million; net loss was $110.535 million versus $113.5 million.
9M operating cash use was $112.3 million; investing activities provided $114.1 million, mainly from securities sales and maturities.
Outlook and guidance
C-FORWARD topline results are expected in Q1 2027; pending positive results, a US NDA submission is targeted for Q2 2027 or mid-2027, with an EMA submission targeted for late 2027.
Cash, cash equivalents and investments, together with the initial $65 million facility draw, are expected to fund planned operations into mid-2028; additional borrowing is conditional on milestones and other terms.
AT-587 Phase 1 results are expected early 2027; a proof-of-concept study is planned for H1 2027, with preliminary results expected late 2027.
Planned spending includes HCV Phase 3 completion, NDA-enabling and commercial-scale manufacturing work, potential launch preparation, and HEV development.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Atea Pharmaceuticals
- Eight-week hepatitis C regimen achieves strong phase III results, with NDA filing planned for next year.AVIR
Morgan Stanley 24th Annual Global Healthcare Conference - BEM/RZR met Phase 3 endpoints, supporting NDA plans for HCV in 2027 and strong commercial prospects.AVIRQ2 2026
- Director elections, clinical milestones, and strong financials marked the meeting's key outcomes.AVIRAGM 2026
- Phase 3 HCV trials advance toward 2026 readouts as R&D drives higher net loss and cash supports runway.AVIRQ1 2026
- Key votes include director elections, auditor ratification, and executive pay approval.AVIRProxy filing
- Proxy covers director elections, auditor ratification, and performance-based executive pay.AVIRProxy filing
- Phase III HCV and HEV programs advance, topline results in 2026, cash $301.8M, net loss $158.4M.AVIRQ4 2025
- Pivotal COVID-19 and HCV trial results due late 2024; $502.2M cash funds operations into 2027.AVIRQ2 2024
- Strong phase II HCV results and a pivotal COVID-19 trial set up major milestones for late 2024.AVIRJefferies 2024 Global Healthcare Conference
Next Atea Pharmaceuticals earnings date
Q4 20265 Mar, 2027
Atea Pharmaceuticals
Next Atea Pharmaceuticals earnings date
Q4 20265 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for the treatment of viral diseases. The company's research and development efforts primarily target diseases such as hepatitis C, dengue, and COVID-19. Atea leverages its expertise in nucleoside and nucleotide therapeutics to create treatments aimed at addressing unmet medical needs in the antiviral space. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.